Table Info

Table 1.

Similarity and differences in features of SMZL, HCL, and SDRPL

Features	Type of feature	SMZL	HCL	SDRPL
Demographics	Incidence	0.13/100,000	0.4/100,000	?
	Median age	65–69	55–63	70
	M:F ratio	1:1.1 to 1:1.85	3:1 to 4:1	1.6:1 to 2.4:1
Immunophenotype	CD25	+	++	-
	CD27	++	--	-
	CD5	+	-	-
	CD200	-	++	-
Outcome	Need for treatment	70%	Yes	50%
Outcome	Transformation	10–20% into DLBCL	5–6%	Rarely

+: indicates positive; ++: indicates strong positive; -: indicates negative; --: indicates strong negative; ?: unknown. SMZL: splenic marginal zone lymphoma; HCL: hairy cell leukaemia; DLBCL: diffuse large B-cell lymphoma; SDRPL: splenic diffuse red pulp lymphoma; M:F: male: female

Declarations

Author contributions

AM: Conception, Data curation, Methodology, Project administration, Writing—original draft, Writing—review & editing. HP: Writing—original draft, Writing—review & editing, Supervision. MA, RW, KS, and DB: Writing—original draft, Writing—review & editing. BS: Data curation, Methodology, Writing—original draft, Writing—review & editing. DGO: Conception, Writing—original draft, Writing—review & editing. JG and JCS: Conception, Project administration, Writing—original draft, Writing—review & editing.

Conflicts of interest

Jonathan C. Strefford is the Editorial Board Member of Exploration of Targeted Anti-tumor Therapy, but he had no involvement in the journal review process of this manuscript. The other authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Amatta Mirandari is funded by Cancer Immunology Talent Fund, University of Southampton. Jonathan C. Strefford received funding from the Kay Kendall Leukemia Fund [873, 1104]; and Cancer Research UK ECRIN-M3 accelerator award [C42023/A29370]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Schmid C, Kirkham N, Diss T, Isaacson PG. Splenic marginal zone cell lymphoma. Am J Surg Pathol. 1992;16:455–66. [DOI] [PubMed]

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. [DOI] [PubMed] [PMC]

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48. [DOI] [PubMed] [PMC]

Coupland SE, Du M, Ferry JA, Jong Dd, Khoury JD, Leoncini L, et al.; WHO 5th Edition Classification Project. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research. J Pathol. 2024;262:255–70. [DOI] [PubMed]

Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma. 2013;54:1380–6. [DOI] [PubMed]

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva: WHO Press; 2008.

Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127:2072–81. [DOI] [PubMed]

Chacón JI, Mollejo M, Muñoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648–54. [PubMed]

Donzel M, Baseggio L, Fontaine J, Pesce F, Ghesquières H, Bachy E, et al. New Insights into the Biology and Diagnosis of Splenic Marginal Zone Lymphomas. Curr Oncol. 2021;28:3430–47. [DOI] [PubMed] [PMC]

10.

Pérez-Chacón G, Llobet D, Pardo C, Pindado J, Choi Y, Reed JC, et al. TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice. J Immunol. 2012;189:1053–61. [DOI] [PubMed] [PMC]

11.

Zhang S, Xuan Z, Zhang L, Lu J, Song P, Zheng S. Splenic marginal zone lymphoma: a case report and literature review. World J Surg Oncol. 2020;18:259. [DOI] [PubMed] [PMC]

12.

Bracci PM, Benavente Y, Turner JJ, Paltiel O, Slager SL, Vajdic CM, et al. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014:52–65. [DOI] [PubMed] [PMC]

13.

Santos PD, Panero J, Nagore VP, Stanganelli C, Bezares RF, Slavutsky I. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia. Tumour Biol. 2015;36:8317–24. [DOI] [PubMed]

14.

Xiong W, Lv R, Li H, Li Z, Wang H, Liu W, et al. Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma. Blood Cancer J. 2017;7:e548. [DOI] [PubMed] [PMC]

15.

Arcaini L, Paulli M. Splenic marginal zone lymphoma: hydra with many heads? Haematologica. 2010;95:534–7. [DOI] [PubMed] [PMC]

16.

Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22:487–95. [DOI] [PubMed]

17.

Parker H, McIver-Brown NR, Davis ZA, Parry M, Rose-Zerilli MJJ, Xochelli A, et al. CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up. Blood Adv. 2018;2:1116–9. [DOI] [PubMed] [PMC]

18.

Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo. Ann Oncol. 2020;31:17–29. Erratum in: Ann Oncol. 2023;34:325. [DOI] [PubMed]

19.

Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, Salles G, Berger F, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4:95–103. [DOI] [PubMed]

20.

Camacho FI, Mollejo M, Mateo MS, Algara P, Navas C, Hernández JM, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268–76. [DOI] [PubMed]

21.

Bastidas-Mora G, Beà S, Navarro A, Gine E, Costa D, Delgado J, et al. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. Br J Haematol. 2022;196:146–55. [DOI] [PubMed] [PMC]

22.

Du Y, Wang Y, Li Q, Chang X, Shen K, Zhang H, et al. Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A population-based study. Int J Cancer. 2024;154:969–78. [DOI] [PubMed]

23.

Sun X, Li H, Yang Y, Wu Y, Kang K, Liu Q, et al. Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study. Ann Hematol. 2024; [Epub ahead of print]. [DOI] [PubMed]

24.

Walewska R, Eyre TA, Barrington S, Brady J, Fields P, Iyengar S, et al.; BSH Committee. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br J Haematol. 2024;204:86–107. [DOI] [PubMed]

25.

Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, et al. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018;183:755–65. [DOI] [PubMed]

26.

Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139:573–86. [DOI] [PubMed] [PMC]

27.

Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci. 2005;30:194–204. [DOI] [PubMed]

28.

Clipson A, Wang M, Leval Ld, Ashton-Key M, Wotherspoon A, Vassiliou G, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2015;29:1177–85. [DOI] [PubMed]

29.

Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R, et al. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. Clin Cancer Res. 2015;21:4174–83. [DOI] [PubMed] [PMC]

30.

Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse-Glehen A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia. 2012;26:1638–46. [DOI] [PubMed]

31.

Zaragoza-Infante L, Agathangelidis A, Papaioannou M, Chatzidimitriou A, Stamatopoulos K. The B cell receptor in marginal zone lymphoma ontogeny and evolution. Annals of Lymphoma. 2020;4:10. [DOI]

32.

Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, et al. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015;29:503–7. [DOI] [PubMed]

33.

Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161:81–8. [DOI] [PubMed] [PMC]

34.

Bikos V, Karypidou M, Stalika E, Baliakas P, Xochelli A, Sutton L, et al. An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. Clin Cancer Res. 2016;22:2032–40. [DOI] [PubMed]

35.

Warsame AA, Aasheim H, Nustad K, Trøen G, Tierens A, Wang V, et al. Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. Blood. 2011;118:3331–9. [DOI] [PubMed]

36.

Brisou G, Verney A, Wenner T, Baseggio L, Felman P, Callet-Bauchu E, et al. A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. Haematologica. 2014;99:e197–8. [DOI] [PubMed] [PMC]

37.

Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, Kevie-Kersemaekers AVd, et al. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica. 2021;106:87–97. [DOI] [PubMed] [PMC]

38.

Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood. 2008;112:1993–2003. [DOI] [PubMed] [PMC]

39.

Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116:1479–88. [DOI] [PubMed]

40.

Andersen CL, Gruszka-Westwood A, Atkinson S, Matutes E, Catovsky D, Pedersen RK, et al. Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. Cancer Genet Cytogenet. 2005;156:122–8. [DOI] [PubMed]

41.

Dierlamm J, Pittaluga S, Wlodarska I, Stul M, Thomas J, Boogaerts M, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood. 1996;87:299–307. [PubMed]

42.

Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, et al. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. J Immunother Cancer. 2019;7:22. [DOI] [PubMed] [PMC]

43.

Watkins AJ, Huang Y, Ye H, Chanudet E, Johnson N, Hamoudi R, et al. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis. J Pathol. 2010;220:461–74. [DOI] [PubMed]

44.

Solé F, Salido M, Espinet B, Garcia JL, Climent JAM, Granada I, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 2001;86:71–7. [PubMed]

45.

Robledo C, García JL, Benito R, Flores T, Mollejo M, Martínez-Climent J, et al. Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas. PLoS One. 2011;6:e24939. [DOI] [PubMed] [PMC]

46.

Watkins AJ, Hamoudi RA, Zeng N, Yan Q, Huang Y, Liu H, et al. An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma. PLoS One. 2012;7:e44997. [DOI] [PubMed] [PMC]

47.

Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martínez P, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol. 1999;154:1583–9. [DOI] [PubMed] [PMC]

48.

Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117:1595–604. [DOI] [PubMed]

49.

McKeithan TW, Rowley JD, Shows TB, Diaz MO. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1987;84:9257–60. [DOI] [PubMed] [PMC]

50.

Küppers R. Distinct t(14;19) translocation patterns in atypical chronic lymphocytic leukemia and marginal zone lymphomas. Haematologica. 2024;109:376–8. [DOI] [PubMed] [PMC]

51.

Grau M, López C, Navarro A, Frigola G, Nadeu F, Clot G, et al. Unraveling the genetics of transformed splenic marginal zone lymphoma. Blood Adv. 2023;7:3695–709. [DOI] [PubMed] [PMC]

52.

Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M, Malumbres R, et al. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma. Br J Haematol. 2012;158:712–26. [DOI] [PubMed]

53.

Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S, Walewska R, Forster J, et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 2013;8:e83244. [DOI] [PubMed] [PMC]

54.

Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209:1537–51. [DOI] [PubMed] [PMC]

55.

Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209:1553–65. [DOI] [PubMed] [PMC]

56.

Campos-Martín Y, Martínez N, Martínez-López A, Cereceda L, Casado F, Algara P, et al. Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma. Haematologica. 2017;102:e310–2. [DOI] [PubMed] [PMC]

57.

Lechner M, Engleitner T, Babushku T, Schmidt-Supprian M, Rad R, Strobl LJ, et al. Notch2-mediated plasticity between marginal zone and follicular B cells. Nat Commun. 2021;12:1111. [DOI] [PubMed] [PMC]

58.

Saito T, Chiba S, Ichikawa M, Kunisato A, Asai T, Shimizu K, et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity. 2003;18:675–85. [DOI] [PubMed]

59.

Bonfiglio F, Bruscaggin A, Guidetti F, Bergamo LTd, Faderl M, Spina V, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139:732–747. [DOI] [PubMed]

60.

Rosati E, Baldoni S, Falco FD, Papa BD, Dorillo E, Rompietti C, et al. NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. Front Oncol. 2018;8:229. [DOI] [PubMed] [PMC]

61.

Martinez D, Navarro A, Martinez-Trillos A, Molina-Urra R, Gonzalez-Farre B, Salaverria I, et al. NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. Am J Surg Pathol. 2016;40:192–201. [DOI] [PubMed]

62.

Silkenstedt E, Arenas F, Colom-Sanmartí B, Xargay-Torrent S, Higashi M, Giró A, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019;38:446. [DOI] [PubMed] [PMC]

63.

Kuroda K, Han H, Tani S, Tanigaki K, Tun T, Furukawa T, et al. Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity. 2003;18:301–12. [DOI] [PubMed]

64.

Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009;114:2467–75. [DOI] [PubMed]

65.

Turpaev KT. Transcription Factor KLF2 and Its Role in the Regulation of Inflammatory Processes. Biochemistry (Mosc). 2020;85:54–67. [DOI] [PubMed]

66.

Hoek KL, Gordy LE, Collins PL, Parekh VV, Aune TM, Joyce S, et al. Follicular B cell trafficking within the spleen actively restricts humoral immune responses. Immunity. 2010;33:254–65. [DOI] [PubMed] [PMC]

67.

Winkelmann R, Sandrock L, Kirberg J, Jäck H, Schuh W. KLF2–a negative regulator of pre-B cell clonal expansion and B cell activation. PLoS One. 2014;9:e97953. [DOI] [PubMed] [PMC]

68.

Hart GT, Wang X, Hogquist KA, Jameson SC. Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc Natl Acad Sci U S A. 2011;108:716–21. [DOI] [PubMed] [PMC]

69.

Yan Q, Huang Y, Watkins AJ, Kocialkowski S, Zeng N, Hamoudi RA, et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012;97:595–8. [DOI] [PubMed] [PMC]

70.

Moore CR, Liu Y, Shao C, Covey LR, Morse HC 3rd, Xie P. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia. 2012;26:1122–7. [DOI] [PubMed] [PMC]

71.

Aubrey BJ, Strasser A, Kelly GL. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb Perspect Med. 2016;6:a026062. [DOI] [PubMed] [PMC]

72.

de Groen RAL, Schrader AMR, Kersten MJ, Pals ST, Vermaat JSP. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. Haematologica. 2019;104:2337–48. [DOI] [PubMed] [PMC]

73.

Martinez-Lopez A, Curiel-Olmo S, Mollejo M, Cereceda L, Martinez N, Montes-Moreno S, et al. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol. 2015;39:644–51. [DOI] [PubMed]

74.

Wang S, Charbonnier L, Rivas MN, Georgiev P, Li N, Gerber G, et al. MyD88 Adaptor-Dependent Microbial Sensing by Regulatory T Cells Promotes Mucosal Tolerance and Enforces Commensalism. Immunity. 2015;43:289–303. [DOI] [PubMed] [PMC]

75.

Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Res. 2018;78:2457–62. [DOI] [PubMed]

76.

Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121:2522–8. [DOI] [PubMed]

77.

Alcoceba M, García-Álvarez M, Medina A, Maldonado R, González-Calle V, Chillón MC, et al. MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. Int J Mol Sci. 2022;23:5570. [DOI] [PubMed] [PMC]

78.

Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, et al. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clin Cancer Res. 2016;22:2755–64. [DOI] [PubMed]

79.

Weller S, Bonnet M, Delagreverie H, Israel L, Chrabieh M, Maródi L, et al. IgM⁺IgD⁺CD27⁺ B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP- but not UNC-93B-deficient patients. Blood. 2012;120:4992–5001. [DOI] [PubMed] [PMC]

80.

Zhang J, Dominguez-Sola D, Hussein S, Lee J, Holmes AB, Bansal M, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21:1190–8. [DOI] [PubMed] [PMC]

81.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21:1199–208. [DOI] [PubMed] [PMC]

82.

Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10:440–459. [DOI] [PubMed] [PMC]

83.

Zhang J, Vlasevska S, Wells VA, Nataraj S, Holmes AB, Duval R, et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov. 2017;7:322–37. [DOI] [PubMed] [PMC]

84.

Hernández JM, García JL, Gutiérrez NC, Mollejo M, Martínez-Climent JA, Flores T, et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol. 2001;158:1843–50. [DOI] [PubMed] [PMC]

85.

Remstein ED, Law M, Mollejo M, Piris MA, Kurtin PJ, Dogan A. The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. Leukemia. 2008;22:1268–72. [DOI] [PubMed]

86.

Carbo-Meix A, Guijarro F, Wang L, Grau M, Royo R, Frigola G, et al. BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases. Haematologica. 2024;109:493–508. [DOI] [PubMed] [PMC]

87.

Sasaki Y, Iwai K. Roles of the NF-κB Pathway in B-Lymphocyte Biology. Curr Top Microbiol Immunol. 2016;393:177–209. [DOI] [PubMed]

88.

Liu T, Zhang L, Joo D, Sun S. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. [DOI] [PubMed] [PMC]

89.

Shembade N, Harhaj EW. Regulation of NF-κB signaling by the A20 deubiquitinase. Cell Mol Immunol. 2012;9:123–30. [DOI] [PubMed] [PMC]

90.

Sasaki Y, Derudder E, Hobeika E, Pelanda R, Reth M, Rajewsky K, et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity. 2006;24:729–39. [DOI] [PubMed]

91.

Nagel D, Vincendeau M, Eitelhuber AC, Krappmann D. Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Oncogene. 2014;33:5655–65. [DOI] [PubMed]

92.

Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118:4930–4. [DOI] [PubMed]

93.

Sakakibara S, Espigol-Frigole G, Gasperini P, Uldrick TS, Yarchoan R, Tosato G. A20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi’s sarcoma-associated herpesvirus vFLIP oncoprotein. Oncogene. 2013;32:1223–32. [DOI] [PubMed] [PMC]

94.

Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A. 1996;93:6721–5. [DOI] [PubMed] [PMC]

95.

Zhu S, Jin J, Gokhale S, Lu AM, Shan H, Feng J, et al. Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol. 2018;9:2111. [DOI] [PubMed] [PMC]

96.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87–92. [DOI] [PubMed]

97.

Lenz G, Wright GW, Emre NCT, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105:13520–5. [DOI] [PubMed] [PMC]

98.

Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Ranghetti P, et al. Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. Haematologica. 2015;100:1460–8. [DOI] [PubMed] [PMC]

99.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–9. [DOI] [PubMed] [PMC]

100.

Das H, Kumar A, Lin Z, Patino WD, Hwang PM, Feinberg MW, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A. 2006;103:6653–8. [DOI] [PubMed] [PMC]

101.

Alderuccio JP, Lossos IS. NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy. Leuk Lymphoma. 2022;63:279–90. [DOI] [PubMed]

102.

Garis M, Garrett-Sinha LA. Notch Signaling in B Cell Immune Responses. Front Immunol. 2021;11:609324. [DOI] [PubMed] [PMC]

103.

Kopan R. Notch signaling. Cold Spring Harb Perspect Biol. 2012;4:a011213. [DOI] [PubMed] [PMC]

104.

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675–684. [DOI] [PubMed] [PMC]

105.

Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011;108:17761–6. [DOI] [PubMed] [PMC]

106.

Shanmugam V, Craig JW, Hilton LK, Nguyen MH, Rushton CK, Fahimdanesh K, et al. Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors. Blood Adv. 2021;5:71–83. [DOI] [PubMed] [PMC]

107.

Oquendo CJ, Parker H, Oscier D, Ennis S, Gibson J, Strefford JC. Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma. Sci Rep. 2019;9:10444. [DOI] [PubMed] [PMC]

108.

Gailllard B, Cornillet-Lefebvre P, Le Q, Maloum K, Pannetier M, Lecoq-Lafon C, et al. Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. Br J Haematol. 2021;193:72–82. [DOI] [PubMed]

109.

Spina V, Rossi D. Molecular pathogenesis of splenic and nodal marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30:5–12. [DOI] [PubMed]

110.

Kelso TWR, Porter DK, Amaral ML, Shokhirev MN, Benner C, Hargreaves DC. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. Elife. 2017;6:e30506. [DOI] [PubMed] [PMC]

111.

Lakshminarasimhan R, Andreu-Vieyra C, Lawrenson K, Duymich CE, Gayther SA, Liang G, et al. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. Cancer Lett. 2017;401:11–19. [DOI] [PubMed] [PMC]

112.

Oakes CC, Martin-Subero JI. Insight into origins, mechanisms, and utility of DNA methylation in B-cell malignancies. Blood. 2018;132:999–1006. [DOI] [PubMed]

113.

Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016;48:253–64. [DOI] [PubMed] [PMC]

114.

Arribas AJ, Bertoni F. Methylation patterns in marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30:24–31. [DOI] [PubMed]

115.

Arribas AJ, Rinaldi A, Mensah AA, Kwee I, Cascione L, Robles EF, et al. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood. 2015;125:1922–31. [DOI] [PubMed] [PMC]

116.

Duran-Ferrer M, Clot G, Nadeu F, Beekman R, Baumann T, Nordlund J, et al. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. Nat Cancer. 2020;1:1066–1081. [DOI] [PubMed] [PMC]

117.

Parker H, Mirandari A, Oquendo CJ, Duran-Ferrer M, Stevens B, Buermann L, et al. Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma. medRxiv 24301320 [Preprint]. 2024 [cited 2024 Jan 20]. Available from: https://www.medrxiv.org/content/10.1101/2024.01.16.24301320v1

118.

Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106:1831–8. [DOI] [PubMed]

119.

Trøen G, Nygaard V, Jenssen T, Ikonomou IM, Tierens A, Matutes E, et al. Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. J Mol Diagn. 2004;6:297–307. [DOI] [PubMed] [PMC]

120.

Robinson JE, Greiner TC, Bouska AC, Iqbal J, Cutucache CE. Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential. Front Oncol. 2020;10:640. [DOI] [PubMed] [PMC]

121.

Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524–9. [DOI] [PubMed] [PMC]

122.

Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17:28–40. [DOI] [PubMed]

123.

Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martínez P, Piris MA. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia. 2007;21:2547–9. [DOI] [PubMed]

124.

Arribas AJ, Gómez-Abad C, Sánchez-Beato M, Martinez N, Dilisio L, Casado F, et al. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Mod Pathol. 2013;26:889–901. [DOI] [PubMed]

125.

Peveling-Oberhag J, Crisman G, Schmidt A, Döring C, Lucioni M, Arcaini L, et al. Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. Leukemia. 2012;26:1654–62. [DOI] [PubMed]

126.

Scarola M, Schoeftner S, Schneider C, Benetti R. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res. 2010;70:6925–33. [DOI] [PubMed]

127.

Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 2013;4:e659. [DOI] [PubMed] [PMC]

128.

Yamaguchi K, Abdelbaky S, Arons E, Cross M, Wu YZ, Weigel C, et al. DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma. Blood. 2023;142:174. [DOI]

129.

Hopper MA, Wenzl K, Hartert KT, Krull JE, Dropik AR, Novak JP, et al. Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomas. Hematol Oncol. 2023;41:644–54. [DOI] [PubMed]

130.

Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C, et al. Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18:580–9. [DOI] [PubMed] [PMC]

131.

Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol. 2007;136:286–93. [DOI] [PubMed] [PMC]

132.

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526:519–24. [DOI] [PubMed]

133.

Robbe P, Ridout KE, Vavoulis DV, Dréau H, Kinnersley B, Denny N, et al. Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. Nat Genet. 2022;54:1675–89. [DOI] [PubMed] [PMC]

134.

Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, et al. Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood. 2014;123:1836–49. [DOI] [PubMed]

135.

Anagnostou T, Yang Z, Jalali S, Kim HJ, Larson DP, Tang X, et al. Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma. Leukemia. 2023;37:1485–1498. [DOI] [PubMed]

136.

Tang X, Yang Z, Kim HJ, Anagnostou T, Yu Y, Wu X, et al. Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma. Clin Cancer Res. 2022;28:4322–4335. [DOI] [PubMed] [PMC]

137.

Vincent-Fabert C, Soubeyran I, Velasco V, Parrens M, Jeannet R, Lereclus E, et al. Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells. Cell Mol Immunol. 2019;16:621–4. [DOI] [PubMed] [PMC]